Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib

1 Oct 2018

Abstract excerpt

Abstract Purpose: Resistance is an obstacle of glioma therapy. Despite targeted interventions, tumors harbor primary resistance or become resistant over short course of treatment. This study examined the mouse double minute 2 (MDM2) inhibitor RG7388 together with radiotherapy and analyzed strategies to overcome acquired MDM2 inhibitor resistance in glioblastoma. Experimental Design: Effects of RG7388 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Glioma Diagnosis and Treatment
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30274984
DOI: 10.1158/1078-0432.ccr-18-1580

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor TrametinibPMID 30274984Read ↗

Characterization of Temozolomide Resistance Using a Novel Acquired Resistance Model in Glioblastoma Cell LinesSemantic proximity Read ↗

Preclinical Efficacy of the MDM2 Inhibitor RG7112 in <i>MDM2</i> -Amplified and <i>TP53</i> Wild-type GlioblastomasSemantic proximity Read ↗

Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastomaSemantic proximity Read ↗

MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastomaSemantic proximity Read ↗

An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for GlioblastomaSemantic proximity Read ↗

Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signaturesSemantic proximity Read ↗

Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.Semantic proximity Read ↗

High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors.Semantic proximity Read ↗

The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cellsSemantic proximity Read ↗

An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinasesSemantic proximity Read ↗

Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in GlioblastomaSemantic proximity Read ↗

The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target CompensationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.